Abstract
Although intracavernosal administration of prostaglandin E1 (PGE1) had been performed since the mid-1980s, few data were available from reliable clinical trials. This study provided a rigorous clinical rationale for the continued use of intracorporal PGE1.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
6.1 Key Trial References
6.1.1 Major Publication
Linet O, Ogrinc F. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 334:873–877, 1996.
6.1.2 Other Important Publications
Linet O, Neff L. Intracavernous prostaglandin E1 in erectile dysfunction. Clin Invest 72:139–149, 1989.
Brock G, Tu L, Linet O. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. Urology 57(3): 536–541, 2001.
Rights and permissions
Copyright information
© 2007 Springer-Verlag London Limited
About this chapter
Cite this chapter
(2007). Defining the Therapeutic Ratio for Intracavernosal Administration of Prostaglandin E1 (Alprostadil). In: Key Clinical Trials in Erectile Dysfunction. Springer, London. https://doi.org/10.1007/978-1-84628-428-1_6
Download citation
DOI: https://doi.org/10.1007/978-1-84628-428-1_6
Publisher Name: Springer, London
Print ISBN: 978-1-84628-427-4
Online ISBN: 978-1-84628-428-1
eBook Packages: MedicineMedicine (R0)